These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 22220513)

  • 1. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
    Gunthorpe MJ; Large CH; Sankar R
    Epilepsia; 2012 Mar; 53(3):412-24. PubMed ID: 22220513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use.
    Large CH; Sokal DM; Nehlig A; Gunthorpe MJ; Sankar R; Crean CS; Vanlandingham KE; White HS
    Epilepsia; 2012 Mar; 53(3):425-36. PubMed ID: 22221318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels.
    Brickel N; Gandhi P; VanLandingham K; Hammond J; DeRossett S
    Epilepsia; 2012 Apr; 53(4):606-12. PubMed ID: 22428574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy.
    Brodie MJ; Lerche H; Gil-Nagel A; Elger C; Hall S; Shin P; Nohria V; Mansbach H;
    Neurology; 2010 Nov; 75(20):1817-24. PubMed ID: 20944074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data.
    Orhan G; Wuttke TV; Nies AT; Schwab M; Lerche H
    Expert Opin Pharmacother; 2012 Aug; 13(12):1807-16. PubMed ID: 22783830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate.
    Wuttke TV; Seebohm G; Bail S; Maljevic S; Lerche H
    Mol Pharmacol; 2005 Apr; 67(4):1009-17. PubMed ID: 15662042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy.
    French JA; Abou-Khalil BW; Leroy RF; Yacubian EM; Shin P; Hall S; Mansbach H; Nohria V;
    Neurology; 2011 May; 76(18):1555-63. PubMed ID: 21451152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channels.
    Zhang D; Thimmapaya R; Zhang XF; Anderson DJ; Baranowski JL; Scanio M; Perez-Medrano A; Peddi S; Wang Z; Patel JR; DeGoey DA; Gopalakrishnan M; Honore P; Yao BB; Surowy CS
    J Neurosci Methods; 2011 Aug; 200(1):54-62. PubMed ID: 21723881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retigabine as adjunctive therapy in adults with partial-onset seizures: integrated analysis of three pivotal controlled trials.
    Porter RJ; Burdette DE; Gil-Nagel A; Hall ST; White R; Shaikh S; DeRossett SE
    Epilepsy Res; 2012 Aug; 101(1-2):103-12. PubMed ID: 22512894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site.
    Padilla K; Wickenden AD; Gerlach AC; McCormack K
    Neurosci Lett; 2009 Nov; 465(2):138-42. PubMed ID: 19733209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of different titration rates of retigabine (ezogabine) in patients with partial-onset seizures.
    Biton V; Gil-Nagel A; Brodie MJ; Derossett SE; Nohria V
    Epilepsy Res; 2013 Nov; 107(1-2):138-45. PubMed ID: 24094693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequence determinants of subtype-specific actions of KCNQ channel openers.
    Wang AW; Yang R; Kurata HT
    J Physiol; 2017 Feb; 595(3):663-676. PubMed ID: 27506413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties.
    Peretz A; Degani N; Nachman R; Uziyel Y; Gibor G; Shabat D; Attali B
    Mol Pharmacol; 2005 Apr; 67(4):1053-66. PubMed ID: 15598972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retigabine for partial onset seizures.
    Rheims S; Ryvlin P
    Expert Rev Neurother; 2012 May; 12(5):509-17. PubMed ID: 22550979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine.
    Schenzer A; Friedrich T; Pusch M; Saftig P; Jentsch TJ; Grötzinger J; Schwake M
    J Neurosci; 2005 May; 25(20):5051-60. PubMed ID: 15901787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of retigabine/ezogabine as adjunctive therapy in adult Asian patients with drug-resistant partial-onset seizures: A randomized, placebo-controlled Phase III study.
    Lim KS; Lotay N; White R; Kwan P
    Epilepsy Behav; 2016 Aug; 61():224-230. PubMed ID: 27376872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of KCNQ channel activation in 2 potassium channelopathy mouse models of epilepsy.
    Vanhoof-Villalba SL; Gautier NM; Mishra V; Glasscock E
    Epilepsia; 2018 Feb; 59(2):358-368. PubMed ID: 29265344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus.
    Kalappa BI; Soh H; Duignan KM; Furuya T; Edwards S; Tzingounis AV; Tzounopoulos T
    J Neurosci; 2015 Jun; 35(23):8829-42. PubMed ID: 26063916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive use of ezogabine/retigabine with either traditional sodium channel blocking antiepileptic drugs (AEDs) or AEDs with other mechanisms of action: Evaluation of efficacy and tolerability.
    Brodie MJ; French JA; McDonald SA; Lee WJ; Adams B; Scott A; Nohria V; DeRossett S
    Epilepsy Res; 2014 Jul; 108(5):989-94. PubMed ID: 24726452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potassium channels: how genetic studies of epileptic syndromes open paths to new therapeutic targets and drugs.
    Cooper EC
    Epilepsia; 2001; 42 Suppl 5():49-54. PubMed ID: 11887968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.